skip to content
Resuming Production of the Anthrax Vaccine as Quickly as Possible: Analysis of Alternative Business Arrangements, Volume 1: Main Report Preview this item
ClosePreview this item
Checking...

Resuming Production of the Anthrax Vaccine as Quickly as Possible: Analysis of Alternative Business Arrangements, Volume 1: Main Report

Author: Thomas P FrazierMaria BorgaJohn W BaileyAlec W SalernoJohn J CloosAll authors
Publisher: Ft. Belvoir Defense Technical Information Center OCT 2000.
Edition/Format:   eBook : English
Database:WorldCat
Summary:
A series of technical problems has delayed FDA approval for BioPort Corporation to deliver anthrax vaccine adsorbed (AVA) to the DoD. BioPort is preparing for a new FDA review, and the DoD is providing both financial relief and technical assistance to augment BioPort's efforts. Under this strategy, the earliest BioPort could gain FDA approval and resume AVA delivery is late May 2001. A more realistic expectation is  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

 

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Material Type: Internet resource
Document Type: Internet Resource
All Authors / Contributors: Thomas P Frazier; Maria Borga; John W Bailey; Alec W Salerno; John J Cloos; INSTITUTE FOR DEFENSE ANALYSES ALEXANDRIA VA.
OCLC Number: 227952060
Notes: Prepared in cooperation with Rand Corporation.
Description: 43 p.

Abstract:

A series of technical problems has delayed FDA approval for BioPort Corporation to deliver anthrax vaccine adsorbed (AVA) to the DoD. BioPort is preparing for a new FDA review, and the DoD is providing both financial relief and technical assistance to augment BioPort's efforts. Under this strategy, the earliest BioPort could gain FDA approval and resume AVA delivery is late May 2001. A more realistic expectation is delivery in the first half of 2002. IDA and the RAND Corporation studied the advantages and disadvantages of the DoD purchasing BioPort's Lansing, Michigan, AVA-production facility and converting it to a government-owned, contractor-operated (GOCO) operation. In one scenario, the DoD would select a new company to run the facility; in another, the DoD would have BioPort run the facility. We found that neither Option would result in vaccine being delivered faster than under the current strategy. Under the first GOCO scenario, the earliest AVA could be delivered would be 2003 (more probably late 2004). Under the second scenario, the earliest delivery date would be August 2001 (more probably late 2002). This report is the first of two volumes.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


<http://www.worldcat.org/oclc/227952060>
library:oclcnum"227952060"
library:placeOfPublication
library:placeOfPublication
owl:sameAs<info:oclcnum/227952060>
rdf:typeschema:Book
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:bookFormatschema:EBook
schema:contributor
<http://viaf.org/viaf/132161523>
rdf:typeschema:Organization
schema:name"INSTITUTE FOR DEFENSE ANALYSES ALEXANDRIA VA."
schema:contributor
schema:contributor
schema:contributor
schema:contributor
schema:contributor
schema:datePublished"OCT 2000"
schema:datePublished"2000"
schema:description"A series of technical problems has delayed FDA approval for BioPort Corporation to deliver anthrax vaccine adsorbed (AVA) to the DoD. BioPort is preparing for a new FDA review, and the DoD is providing both financial relief and technical assistance to augment BioPort's efforts. Under this strategy, the earliest BioPort could gain FDA approval and resume AVA delivery is late May 2001. A more realistic expectation is delivery in the first half of 2002. IDA and the RAND Corporation studied the advantages and disadvantages of the DoD purchasing BioPort's Lansing, Michigan, AVA-production facility and converting it to a government-owned, contractor-operated (GOCO) operation. In one scenario, the DoD would select a new company to run the facility; in another, the DoD would have BioPort run the facility. We found that neither Option would result in vaccine being delivered faster than under the current strategy. Under the first GOCO scenario, the earliest AVA could be delivered would be 2003 (more probably late 2004). Under the second scenario, the earliest delivery date would be August 2001 (more probably late 2002). This report is the first of two volumes."@en
schema:exampleOfWork<http://worldcat.org/entity/work/id/137589007>
schema:inLanguage"en"
schema:name"Resuming Production of the Anthrax Vaccine as Quickly as Possible: Analysis of Alternative Business Arrangements, Volume 1: Main Report"@en
schema:numberOfPages"43"
schema:publisher
schema:url<http://handle.dtic.mil/100.2/ADA388211>
schema:url

Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.